{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T03:13:41Z","timestamp":1770779621808,"version":"3.50.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:p>We report a case of anti-protein death 1-induced sarcoid-like reaction in a 63-year-old Caucasian male who was diagnosed with stage IV-M1a melanoma. He was initially treated with pembrolizumab monotherapy (Q3W) and had a complete response after 14 cycles. However, relapse was suspected 3 months later with appearance of hilar, mediastinal and hepatic hilar lymph nodes as well as a skin lesion. Biopsy of both the hilar lymph nodes and the skin lesion demonstrated sarcomatoid granulomatosis. Pembrolizumab was discontinued temporarily. While on <jats:sup>18<\/jats:sup>F-FDG-PET\/CT, all sarcoid-like lesions regressed in size and activity, a new hypermetabolic solitary skeletal lesion was detected in a lumbar vertebra, suspicious for metastasis. However, since the patient was asymptomatic, a watchful-waiting attitude was taken. During this period, a spontaneous and complete resolution of the metabolic activity was observed of the skeletal lesion. Until today, the patient remains in complete remission. Current case presents an atypical presentation and evolution of anti-PD-1-induced sarcoid-like reaction, illustrating the difficulty of differentiating it from disease progression. Before considering (re-)initiation of anti-melanoma therapy, a tissue biopsy of one of the suspected lesions may be performed to confirm diagnosis. Physicians treating patients with ICI should be aware of this difficulty and critically assess the nature of lesions suspect of progression in patients responding to ICI and presenting with a sarcoid-like reaction.<\/jats:p>","DOI":"10.1097\/cmr.0000000000000680","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T22:01:25Z","timestamp":1596060085000},"page":"524-527","source":"Crossref","is-referenced-by-count":9,"title":["An atypical sarcoid-like reaction during anti-protein death 1 treatment in a patient with metastatic melanoma"],"prefix":"10.1097","volume":"30","author":[{"given":"Stijn De","family":"Keukeleire","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, UZ Gent, Gent"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Schwarze","sequence":"additional","affiliation":[{"name":"Medical Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gil","family":"Awada","sequence":"additional","affiliation":[{"name":"Medical Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrik","family":"Everaert","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Marie","family":"Van Binst","sequence":"additional","affiliation":[{"name":"Radiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Cras","sequence":"additional","affiliation":[{"name":"Anatomopathology, UZ Brussel \u2013 VUB, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Neyns","sequence":"additional","affiliation":[{"name":"Medical Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Aspeslagh","sequence":"additional","affiliation":[{"name":"Medical Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,7,21]]},"reference":[{"key":"R1-20230902","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"R2-20230902","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma.","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"R3-20230902","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"R4-20230902","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2018.03.006","article-title":"Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1.","volume":"96","author":"Mekki","year":"2018","journal-title":"Eur J Cancer"},{"key":"R5-20230902","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/CMR.0000000000000541","article-title":"18F-FDG PET\/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab.","volume":"29","author":"Sachpekidis","year":"2019","journal-title":"Melanoma Res"},{"key":"R6-20230902","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III Melanoma.","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"R7-20230902","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/CMR.0000000000000437","article-title":"Sarcoid-like reactions in patients receiving modern melanoma treatment.","volume":"28","author":"Dimitriou","year":"2018","journal-title":"Melanoma Res"},{"key":"R8-20230902","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jtho.2018.04.031","article-title":"Sarcoidosis-like reactions induced by checkpoint inhibitors.","volume":"13","author":"Gkiozos","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R9-20230902","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-019-0096-x","article-title":"Sarcoidosis.","volume":"5","author":"Grunewald","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"R10-20230902","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S1470-2045(18)30252-3","article-title":"Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases.","volume":"19","author":"Jespersen","year":"2018","journal-title":"Lancet Oncol"},{"key":"R11-20230902","first-page":"1355","article-title":"Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor.","volume":"32","author":"Wilgenhof","year":"2012","journal-title":"Anticancer Res"},{"key":"R12-20230902","doi-asserted-by":"crossref","first-page":"e954506","DOI":"10.4161\/21624011.2014.954506","article-title":"Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab.","volume":"3","author":"Andersen","year":"2014","journal-title":"Oncoimmunology"},{"key":"R13-20230902","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jdcr.2016.06.004","article-title":"Pembrolizumab-associated sarcoidosis.","volume":"2","author":"Cotliar","year":"2016","journal-title":"JAAD Case Rep"},{"key":"R14-20230902","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1177\/1078155216667635","article-title":"Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors.","volume":"23","author":"Firwana","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"R15-20230902","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s40425-016-0199-9","article-title":"Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature.","volume":"4","author":"Reuss","year":"2016","journal-title":"J Immunother Cancer"},{"key":"R16-20230902","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.rmr.2018.08.003","article-title":"Sarcoid-like granulomatosis in cancer patients treated with immune checkpoints inhibitors.","volume":"35","author":"Faviez","year":"2018","journal-title":"Rev Mal Respir"},{"key":"R17-20230902","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/1756-185X.13076","article-title":"Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: case series and immunophenotypic analysis.","volume":"20","author":"Lomax","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"R18-20230902","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1159\/000502285","article-title":"Hypercalcaemia due to sarcoidosis during treatment with avelumab for metastatic merkel cell carcinoma.","volume":"12","author":"Tun Min","year":"2019","journal-title":"Case Rep Oncol"},{"key":"R19-20230902","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy.","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"R20-20230902","doi-asserted-by":"crossref","first-page":"vii59","DOI":"10.1093\/rheumatology\/kez308","article-title":"Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.","volume":"58","author":"Weinmann","year":"2019","journal-title":"Rheumatology (Oxford)"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0000000000000680","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T04:05:02Z","timestamp":1693627502000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0000000000000680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,21]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0000000000000680","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,21]]}}}